Articles by tag: fda-fast-track

FDA Fast Track for ADC ZW191 against resistant ovarian cancer

ADC ZW191 received Fast Track status from FDA for platinum-resistant ovarian cancer. ORR 64%, works with low FRα expression. Learn about the breakthrough and risks.

FDA Fast Track for dendritic cell therapy dubodencel in melanoma

FDA granted Fast Track status to dubodencel (DOC1021) therapy for the treatment of unresectable melanoma. Learn how personalized dendritic cell vaccine is changing oncoimmunology.